Q4 2024 EPS Estimates for ACADIA Pharmaceuticals Inc. Reduced by Zacks Research (NASDAQ:ACAD)
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) – Analysts at Zacks Research dropped their Q4 2024 earnings per share (EPS) estimates for shares of ACADIA Pharmaceuticals in a research note issued to investors on Tuesday, December 5th. Zacks Research analyst A. Chakraborty now expects that the biopharmaceutical company will post earnings per share of $0.22 […]
More Stories
Iran Offered Better Deal ‘10 Minutes’ After US Canceled Pakistan Meeting, Trump Says
By Jacki Thrapp The Iranian regime offered the United States a “much better” peace deal within 10 minutes of President...
Iran Delegation Leaves Pakistan Without US Talks as Trump Cancels Envoy Visit
By Tom Ozimek Iranian Foreign Minister Abbas Araghchi left Pakistan for Oman on Saturday without meeting U.S. negotiators. Araghchi met...
SBA Refers 562,000 Suspected Fraudulent Loans Worth $22.2 Billion to Treasury
By Naveen Athrappully The Small Business Administration (SBA) has referred 562,000 loans suspected to be fraudulent to the Treasury Department...
US Exports of Crude and Petroleum Products Hit Record Highs
By Jacki Thrapp America’s energy exports have hit record highs as the world navigates the uncertainty surrounding oil and gas...
New Listings Tick Up 3 Percent as Mortgage Rates Continue to Slide
By Rob Sabo New home listings are on the rise across the United States, potentially spurred by hopes of falling...
US, EU Sign Preliminary Partnership Deal on Critical Minerals
By Owen Evans The United States and the European Union signed a memorandum of understanding on April 24 for a...